![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PAGE5 |
Gene summary for PAGE5 |
![]() |
Gene information | Species | Human | Gene symbol | PAGE5 | Gene ID | 90737 |
Gene name | PAGE family member 5 | |
Gene Alias | CT16 | |
Cytomap | Xp11.21 | |
Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q96GU1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
90737 | PAGE5 | S014 | Human | Liver | HCC | 4.47e-77 | 2.25e+00 | 0.2254 |
90737 | PAGE5 | S015 | Human | Liver | HCC | 6.83e-29 | 2.02e+00 | 0.2375 |
90737 | PAGE5 | S016 | Human | Liver | HCC | 1.04e-84 | 2.47e+00 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PAGE5 | SNV | Missense_Mutation | c.177N>C | p.Glu59Asp | p.E59D | Q96GU1 | protein_coding | deleterious(0.03) | possibly_damaging(0.908) | TCGA-A2-A0D2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
PAGE5 | SNV | Missense_Mutation | novel | c.167N>C | p.Arg56Pro | p.R56P | Q96GU1 | protein_coding | tolerated(1) | benign(0.009) | TCGA-C8-A3M8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |
PAGE5 | insertion | Frame_Shift_Ins | novel | c.52_52+1insATCATTGCAAGCATGACAGCAGACTCGC | p.Val18AspfsTer15 | p.V18Dfs*15 | Q96GU1 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
PAGE5 | SNV | Missense_Mutation | novel | c.361A>G | p.Lys121Glu | p.K121E | Q96GU1 | protein_coding | tolerated(0.19) | benign(0.045) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
PAGE5 | SNV | Missense_Mutation | novel | c.338N>T | p.Thr113Ile | p.T113I | Q96GU1 | protein_coding | tolerated(0.46) | benign(0.005) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PAGE5 | SNV | Missense_Mutation | novel | c.367C>A | p.Leu123Met | p.L123M | Q96GU1 | protein_coding | tolerated(0.09) | probably_damaging(0.958) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PAGE5 | SNV | Missense_Mutation | novel | c.258N>A | p.Asp86Glu | p.D86E | Q96GU1 | protein_coding | tolerated(0.27) | probably_damaging(0.994) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
PAGE5 | SNV | Missense_Mutation | novel | c.85N>A | p.Gln29Lys | p.Q29K | Q96GU1 | protein_coding | tolerated(0.58) | benign(0.022) | TCGA-AJ-A3OL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
PAGE5 | SNV | Missense_Mutation | novel | c.304N>A | p.Ala102Thr | p.A102T | Q96GU1 | protein_coding | tolerated(0.07) | benign(0.052) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
PAGE5 | SNV | Missense_Mutation | novel | c.205N>A | p.Ala69Thr | p.A69T | Q96GU1 | protein_coding | tolerated(1) | possibly_damaging(0.864) | TCGA-AX-A063-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |